Cincinnati Children’s Cancer & Blood Diseases Institute is investing $85 million in expanding its clinical and integrated translational research programs in (1) precision medicine & drug discovery, (2) cellular & immune cancer therapy, (3) advanced proton & FLASH therapy, (4) young adult oncology, and (5) next-generation care navigation. Our mission is to use disruptive and innovative team science to cure high-risk and relapsed cancers. We have a culture of collaboration and compassion with stretch goals and ambitious key results.
We seek dynamic and outstanding individuals at all faculty levels with a career focus in academic translational research. The Division of Oncology includes 30 academic clinical faculty – with new recruitment positions in our medical subspecialty programs including:
- Gene and Cellular Therapy & Research Center
- Leukemia/Lymphoma Center
- Sarcoma Center
- Neuroblastoma Center
- Liver/Renal Tumor Center
- Proton Therapy & Research Center
Successful applicants must be board-eligible or board-certified in Pediatric Hematology-Oncology with prior training in either Pediatrics or Medicine-Pediatrics. Strong mentorship in clinical care and the development of investigator-initiated studies will be provided, along with integration in our robust “team science” translational oncology programs in pediatric and young adult early phase studies and drug development.
Cincinnati Children's is an exceptional environment for leading-edge translational cancer research and career development. US News ranks us as the #1 pediatric cancer program and the #1 children’s hospital. We have one of the most extensive research programs in the nation - ranking in the top 2 among pediatric institutions for funding from the National Institutes of Health. Cincinnati Children’s is a member of the NCI Pediatric Early Phase Clinical Trials Network, SARC Consortium, Pediatric Brain Tumor Consortium, Department of Defense Neurofibromatosis Consortium, New Approaches to Neuroblastoma Treatment Consortium, Therapeutic Advances in Childhood Leukemia Consortium, Pediatric Bone Marrow Transplant Consortium, and select studies of the POETIC consortia.
The over 100-member Cincinnati Children’s cancer clinical and laboratory research faculty members lead programs that include an extensive pediatric cancer biology effort and national-leading centers in drug discovery and drug development, cellular therapy and viral vector GLP production, proton therapy and research, cardio-oncology & oncofertility, psycho-oncology, and advanced rehabilitation medicine. The dedicated Cancer and Blood Diseases Institute clinical trials office has a staff of 90. It supports over 500 active clinical trials, including first-in pediatric investigator-initiated clinical trials with INDs & IDEs, and coordination of multi-site studies.
Our team science approach led to the recent FDA pediatric approvals of the new drugs Vyxeos for acute myeloid leukemia, and selumetinib for patients with inoperable neurofibromatosis tumors. Our first-in-human FLASH proton therapy clinical trial was named one of the top 10 advances in physics for 2022.
Cincinnati Children’s is constructing a $60 million 111,000-square-foot cGMP Applied Gene and Cell Therapy Center, expanding our clinical trials of innovative drugs and biological therapeutics for patients with cancer, blood diseases, or genetic disorders.
Multiple cores support basic and translational research, including genomics, high-density data informatics/systems biology, pharmacology, mouse models of cancer, stem cell and gene/viral vector therapy, organoid medicine, and a growing cellular therapy program.
Contact - Please email cover letter & curriculum vitae to:
John Perentesis, MD FAAP
Professor of Pediatrics, University of Cincinnati College of Medicine
Kleisinger Chair and Director of Oncology & Cancer Programs
Cincinnati Children’s Hospital Medical Center
email: perww3@cchmc.org
Requirements
ABP Board-eligible or board-certified in Pediatric Hematology-Oncology
Including board certification in either Pediatrics or Medicine-Pediatrics
MD or DO or MBBS
#J-18808-Ljbffr
